Spasmalgon, 5 ml 10 pcs

Spasmalgon is a spasmoanalgesic of combined composition.

Methamisole sodium is a derivative of pyrazolone. It has analgesic, antipyretic and anti-inflammatory effects, the mechanism of which is associated with inhibition of prostaglandin synthesis.

Pitophenone hydrochloride is a myotropic antispasmodic; it has a direct effect on the smooth muscles of internal organs and causes their relaxation.

Phenpiperinia bromide, being a m-cholinoblocker, has an additional relaxing effect on the smooth muscles.

The combination of the three components of the drug leads to a mutual enhancement of their pharmacological action.

Indications

Active ingredient

Composition

1 ml of the solution contains:

The active ingredients:

Sodium metamizole 500.0 mg, phenpivery bromide – 0.02 mg, pitophenone hydrochloride – 2.0 mg.

Excipients: water for injection – up to 1 ml.

How to take, the dosage

Intramuscularly 2 – 5 ml of the injectable solution 2-3 times a day. Before injecting the injection solution it should be warmed in the hand.

The duration of treatment is not more than 5 days. The maximum daily dose should not exceed 10 ml of injectable solution (respectively, 5 g of sodium metamizole).

In case of absence of therapeutic effect the drug is discontinued, and in case of good or satisfactory effect the drug is switched to oral or rectal use.

The duration of the course of treatment is determined depending on the clinical symptomatology and etiopathogenesis of the disease.

Interaction

Simultaneous use of Spasmalgon with other non-narcotic analgesics may lead to mutual enhancement of toxic effects.

Sedatives and tranquilizers increase the analgesic effect of sodium metamizole.

Tricyclic antidepressants, oral contraceptives, allopurinol impair metabolism of metamizole in the liver and increase its toxicity.

Barbiturates, phenylbutazone and other inducers of microsomal liver enzymes weaken the effects of sodium metamizole.

Rentgen contrast drugs, colloidal blood substitutes and penicillin should not be used during treatment with drugs containing sodium metamizole.

Simultaneous use with cyclosporine reduces the blood level of the latter.

Sodium metamizole displaces oral hypoglycemic drugs, indirect anticoagulants, glucocorticoids and indomethacin from binding to plasma proteins and may increase their potency.

When co-administered with H 1 -histamine receptor blockers, butyrophenones, phenothiazines, tricyclic antidepressants, amantadine and quinidine may increase m-cholinoblocking action.

It enhances the effects of ethanol.

Concomitant use with chlorpromazine or other phenothiazine derivatives may result in marked hyperthermia.

Thiamazole and cytostatics increase the risk of leukopenia. The effect is enhanced by codeine, H 2 -histamine receptor blockers and propranololol (slows inactivation of sodium metamizole).

Consult a physician if simultaneous use of the above and other medicinal products is necessary.

Special Instructions

In patients suffering from bronchial asthma, taking the drug may provoke a seizure.

When using the drug it is necessary to monitor peripheral blood count (leukocyte count) and liver function.

In case of suspected agranulocytosis or thrombocytopenia the drug should be discontinued.

Alcohol should not be taken during treatment with the drug.

The effect of the drug on the ability to drive vehicles and other mechanisms requiring high concentration

When taking the drug, it is not recommended to drive vehicles and engage in potentially dangerous activities requiring rapid physical and mental reaction.

Contraindications

Hepatic/liver failure; bronchial asthma; bronchial asthma urticaria or acute rhinitis provoked by taking acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs tendency to arterial hypotension hypersensitivity to other nonsteroidal anti-inflammatory drugs.

Side effects

Allergic reactions: urticaria (including conjunctivitis and mucous membranes of the nasopharynx) angioedema in rare cases – malignant exudative erythema (Stephen-Johnson syndrome) toxic epidermal necrolysis (Lyell syndrome) bronchospastic syndrome anaphylactic shock.

Hematopoietic organs: agranulocytosis leukopenia thrombocytopenia. Other: decreased blood pressure (BP).

Anticholinergic effects: dry mouth decreased sweating paresis of accommodation tachycardia difficult urination.

Local reactions: with intramuscular injection infiltrates are possible at the injection site.

Overdose

Symptoms: vomiting, dry mouth, decreased perspiration, impaired accommodation, decreased blood pressure, drowsiness, confusion, liver and kidney dysfunction, seizures.

Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

Pregnancy use

Systematic use of the drug in the first and last trimester of pregnancy and during breastfeeding is excluded. If it is impossible to avoid the use of the drug it is necessary to stop breastfeeding for this period of time.

Similarities